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Abstract
Background: Small vessel vasculitides are known to follow a devastating course towards end-
stage renal disease, unless treated with immunosuppressive regiments. We investigated the value
of clinical, histological and immunohistochemical parameters as predictors of outcome at diagnosis
in patients with pauci immune necrotizing glomerulonephritis.
Methods:  In 34 patients the percentage and evolution stage of crescents, the presence of
glomerular necrosis, the degree or severity of arteriosclerosis, as well as the extent of
tubulointerstitial infiltration, interstial fibrosis and tubular atrophy were assessed. Monoclonal
antibodies were used to identify infiltrating macrophages, α-SMA(+) and PCNA(+) cells, the
expression of integrins α3β1 and LFA-1β, the adhesion molecule ICAM-1, the growth factor TGF-
β1 and the terminal complement component C5b-9.
Results: 24 pts (70.6%) showed a complete or partial response to the treatment. The follow-up
period was 20 ± 22 months. At multivariate analysis, serum CRP (p = 0.024), the intensity of tubular
expression of C5b-9 (p < 0.0001) as well as the extent of glomerular and tubular expression of
α3β1 integrin (p = 0.001 and 0.008 respectively) independently predicted the response to
treatment. The response rate was better in ANCA(+) pts (p = 0.008). The extent of interstitial
infiltrate (p < 0.0001), the severity of tubulointerstitial fibrosis (p < 0.0001) and the severity of
tubular TGF-β1 expression (p < 0.0001) were independent predictors of long term outcome of
renal function.
Conclusion: Patients with ANCA-associated renal vasculitis seem to respond better to the
treatment. Acute phase reactants, such as CRP, implying a more intense parenchymal inflammatory
reaction, as well as the intensity of the de novo expression of C5b-9 and the glomerular and tubular
expression of α3β1 integrin predict the response to therapy. The severity of TIN lesions and of
the tubulo-interstitial TGF-β1 and C5b-9 expression predict an unfavourable outcome.
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Background
Idiopathic pauci immune rapidly progressive glomeru-
lonephritis (IRPGN) with few or no deposits in immun-
ofluorescence is a form of renal vasculitis that occurs
either as a manifestation of a systemic disease, such as
Wegener's granulomatosis and microscopic polyangiitis,
or as renal limited vasculitis[1]. Since the Chapel Hill
Consensus Conference and the association of these dis-
eases with antineutrophil cytoplasmic autoantibodies
(ANCA), the reported incidence has raised (~20 cases per
million) with geographical and seasonal variations and a
known preponderance for older patients[1,2].
The natural course of the disease renders it a "medical
emergency", as the decline in renal function is relentless
and leads to end stage renal failure in a few weeks or
months. Prognosis of IRPGN is a major concern for
patients and physicians, especially because treatment with
corticosteroids and cyclophosphamide, though effective
in controlling disease, is associated with significant mor-
bidity and mortality. Initiating aggressive immunosup-
pressive therapy in order to regain or conserve
independent renal function in patients with IRPGN there-
fore depends upon the perceived prognosis of the patient.
The identification of specific prognostic factors in IRPGN
has been the subject of many studies, which often showed
contradictory results [3-8]. Comparison between these
studies is difficult due to large differences in study design,
inclusion criteria, biopsy-scoring methods, treatment
strategies and end-point definitions.
The aim of the present study was to analyze our experi-
ence with patients with IRPGN that were diagnosed and
followed in one single center. Furthermore, an attempt
was made to identify clinical, histological and immuno-
histochemical findings predictive of response to treatment
and outcome.
Methods
For the purpose of the study clinical and histological data
from 34 adult patients (>15 years of age) with biopsy
proven focal necrotizing glomerulonephritis and/or
glomerular crescents were studied. On immunofluores-
cence there were few or no immune-deposits. All patients
included in the study had sufficient frozen renal tissue for
the immunohistological study. Secondary forms of
IRPGN were excluded on the basis of history, physical and
laboratory examination findings and follow-up. In partic-
ular, patients with immune-complex diseases, such as
lupus, Henoch Schoenlein purpura, cryoglobulinemia,
postinfectious glomerulonephritis and patients with anti-
GBM disease were excluded. In addition, exclusion criteria
included pregnancy, previous malignancy, known HIV
positivity, regular use of drugs that have been implicated
in causing RPGN and hepatitis B antigenemia (HBe anti-
gen positivity).
The presence of extrarenal manifestations and the involve-
ment of other organs were systematically recorded. The
patients were screened for the presence of ANCA. For the
detection of ANCA an indirect immunofluorescence
based on Wiik's method was used[9], while major ANCA
subtypes (MPO, myeloperoxidase and PR3, proteinase 3)
were determined by an Elisa method (Varelisa for MPO-
and PR3-ANCA, Pharmacia-Upjohn).
The treatment protocol consisted of methylprednisolone
iv boluses at a dose 7–15 mg/kg BW (max. 1 g) daily for
three consecutive days followed by oral prednisone at a
daily dose of 1 mg/kg BW with progressive tappering. In
addition to corticosteroids, oral cyclophosphamide at a
daily dose of 1.5–2 mg/kg BW was given in order to main-
tain WBC count above 3,000/mm3. Plasma exchange was
added in case of severe renal impairment necessitating
dialysis, in patients with pulmonary hemorrhage, or in
those with disease progression or persistence of active dis-
ease.
Data collection was recorded at follow-up visits at 1, 3, 6
months after discharge and at 6-month interval until the
end of the study. In compliance with the Helsinki Decla-
ration, informed verbal consent was obtained from all
patients prior to enrollment, allowing for the use of the
patient data and of a tissue sample from their biopsy spec-
imens. The study was approved by the Scientific Commit-
tee of the 'Hippokration' General Hospital. The authors
declare that they have no competing interests.
Definitions
Normal renal function was defined as plasma creatinine
(pCr) ≤ 1.4 mg/dl. Renal insufficiency was defined as per-
sistent rise of pCr >1.4 mg/dl and ESRD was the point at
which dialysis treatment was deemed permanent or when
pCr remained above or equal to 10 mg/dl. A response to
treatment was defined as improvement of renal function
observed within 2 months following initiation of treat-
ment. The response was defined as complete when renal
function returned to normal, as partial when renal func-
tion stabilized at levels not requiring dialysis, while non
response was defined when renal function did not
improved or deteriorated necessitating replacement treat-
ment. Clinical end-points of the present study were the
institution of chronic dialysis, or death of the patient.
Renal biopsy evaluation
All biopsies were taken at presentation (prior to immuno-
suppressive treatment initiation) using a standard Trucut
needle. In each case, glass slides stained with haematoxy-
lin-eosin, Masson trichrome, periodic acid-Schiff andBMC Nephrology 2006, 7:16 http://www.biomedcentral.com/1471-2369/7/16
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methenamine silver periodic acid-Schiff (Jones) were
available for study. In addition to establishing the diagno-
sis of IRPGN, the following features were recorded: the
percentage of glomeruli with cellular, fibrocellular and
fibrous crescents, the percentage of obsolescent and nor-
mal glomeruli, the presence of segmental glomerular
necrosis. Furthermore, the severity of tubulointerstitial
(TIN) fibrosis, the extent of interstitial inflammatory infil-
trate, the severity of tubular atrophy and the presence of
arteriosclerosis were evaluated and graded on a scale from
0 to 3, according to the pathologist's scoring considering
the affected area of the renal parenchyma (grading 0 when
absent, 1 when <30% was affected, 2 when 31–60% was
affected and 3 when >61% was affected).
Immunohistochemical study
Snap-frozen tissue was available for immunohistochemis-
try. The monoclonal antibodies employed were specific
for monocyte/macrophages (M718, DAKO), HLA-DR
antigen (M704, DAKO), PCNA (M879, DAKO), α-
smooth-muscle-actin (αSMA) (M581-DAKO), LFA-1β
(783, DAKO), transforming growth factor β1 (TGF-β1)
(anti-hLAP, MAB 246, R&D Systems), ICAM-1 (NCL-
CD54, Novocastra), and C5b-9 (M777, DAKO). For the
purposes of the study an indirect immunoperoxidase
technique was used. The glomerular expression of TGF-β1
and C5b-9, the tubulointerstitial expression of TGF-β1
and the expression of C5b-9 and ICAM-1 by the extra-
glomerular vessels were evaluated and graded semi-quan-
titatively on a scale from 0 to 3, with the value '0'
indicating no expression, '1'mild, '2' medium and '3'
intense expression. Tubulointerstitial expression of C5b-9
and ICAM-1 was expressed as the percentage of tubules
expressing the antibodies. The glomerular expression of
ICAM-1 was evaluated as normal, decreased or increased.
The number of glomerular or interstitial monocyte/mac-
rophages, αSMA, LFA-1β and PCNA-positive cells were
expressed as the number of cells per glomerular section or
per interstitial mm2, respectively. HLA-DR expressing cells
were not enumerated in the glomeruli because epithelial
and endothelial glomerular cells normally are stained by
this antibody and, therefore, infiltrating cells cannot be
distinguished readily. The number of interstitial HLA-DR
(+) cells was expressed as cells per mm2. Renal tissue from
nephrectomies served as control.
Statistical analysis
Comparisons of clinical, histological or immunohisto-
chemical data between different subgroups were per-
formed using Student's t-test for unpaired data, as well as
the one-way ANOVA. Relationships between parametrical
parameters were determined using Pearson's correlation
coefficient, while Spearman's correlation coefficient was
used to identify relationships between non-parametric
parameters. Multivariate regression analysis was used to
identify independent predicting factors.
Statistical analysis was performed using a computer pro-
gram package (SPSS 10.1 for Windows, Standard version,
©SPSS.Inc, USA), and a P value of <0.05 was considered
significant.
Results
Patient characteristics
The clinical data of patients are shown in Table 1. Mean
pCr at presentation was 6 ± 4.2 mg/dl and mean C-reac-
tive protein (CRP) levels were 72.8 ± 78 mg/l. Eleven
patients (32.3%) presented with oligoanuria and 14
(41.2%) required renal replacement treatment (RRT).
Plasma exchange treatment was required in 14 of 34
patients (41.2%), the same individuals as required RRT.
The mean number of PE sessions was 8.5/patient (range
4–18) and the mean plasma volume exchanged per ses-
sion was 2.1 lt (range 1–3.5 lt). Twenty-six of our patients
(73%) were ANCA (+) and the ratio MPO: PR3 was 1.9:1.
Extra-renal manifestations were recorded in 68% of the
patients.
Histological findings
The mean number of glomeruli per biopsy was 16 ± 9. The
majority of the crescents were of the cellular type and in
20 of 34 biopsies (59%) focal glomerular necrosis was
observed. Interestingly, no evidence of interstitial fibrosis
or tubular atrophy was noted in 20% and 19% of the
biopsies respectively. Arteriosclerosis was observed in all
but 16% of our patients. In three biopsies there was focal
fibrinoid necrosis with infiltration of lymphocytes and
macrophages of a middle-sized artery. The histological
characteristics are shown in Table 2.
Immunohistological findings
Analysis of the immunohistological findings is shown in
Table 3. Macrophages were localized mainly around the
glomerular capillaries or in the crescents, and to a lesser
extent in the glomerular mesangium. In the interstitium,
macrophage infiltration was observed around the glomer-
ular capsule, especially around the glomerular hilum, as
well as around interstitial arterial vessels. Their distribu-
tion in the interstitium was similar to that of HLA-DR (+)
cells. In addition, clusters of macrophages and, to a lesser
extent, HLA-DR (+) cells were accumulated around the
tubules. PCNA (+) cells were identified in the mesangium,
but also around the glomeruli and the interstitial vessels.
α-SMA expressing cells were identified both in the glomer-
uli and the tubulointerstitium. Glomerular α-SMA (+)
cells were mainly localized in the mesangium and in the
crescents. It is of interest that a significant number of cells
in the Bowman's capsule expressed the α-SMA antigen,
but this expression was less impressive compared to theBMC Nephrology 2006, 7:16 http://www.biomedcentral.com/1471-2369/7/16
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glomerular expression of the antigen. In the tubulointer-
stitium,  α-SMA (+) cells were distributed primarily
around the glomeruli, particularly at sites where breaches
at the Bowman's capsule were detected, around tubules
and extra-glomerular vessels, as well as in heaps in the
interstitial space.
The glomerular ICAM-1 expression was considered nor-
mal, increased or decreased in 37%, 16% and 47% of the
cases, respectively. In addition, 37% (± 12%) of the
tubules showed de novo expression of ICAM-1. TGF-β1
was expressed mainly in the mesangium, in cellular and
fibrocellular crescents, but not in fibrous crescents or
obsolete glomeruli. In contrast, C5b-9 expression
appeared more prominent in fibrous and fibrocellular
crescents than in cellular crescents, while 32% of the
tubules expressed C5b-9. Glomerular expression of TGF-
β1 was noted in 95% of the cases (mild in 11%, moderate
in 37% and intense in 47%). Five percent of the glomeruli
did not express TGF-β1 at all. In the TIN, 89% of the biop-
sies showed TGF-β1 expression (mild in 21%, moderate
in 47% and intense in 21%) and 11% showed no expres-
sion at all. The interstitial TGF-β1 expression was more
prominent at sites of dense cellular infiltration. In addi-
tion, TGF-β1 expression was also noted in tubular cells, as
well as in extra-glomerular vessels.
Table 2: Analysis of pathology findings
Glomerular
Total crescents 61 ± 32%
Cellular crescents 57 ± 44%
Fibrocellular crescents 17 ± 35%
Fibrous crescents 12 ± 23%
Sclerosed glomeruli 28 ± 22%
Focal necrosis 20/34 (59%)
Tubulointerstitial
Absent Mild Medium Intense
Cellular infiltrates 20% 37% 17% 26%
TIN fibrosis 20% 20% 37% 23%
Tubular atrophy 19% 55% 10% 16%
Arterial sclerosis 16% 34% 22% 22%
Abbrev: TIN, tubulointerstitial
Table 1: Clinical characteristics of the patients at diagnosis
n 34
Gender (M:F) 17:17 (ratio 1:1)
Age (years) 55.7 ± 17 (range 25–80 years)
ANCA (yes: no) 26:8 (ratio 3,25:1)
Type of ANCA (MPO: PR3) 17:9 (ratio 1,9:1)
Extrarenal manifestations 23 (67.6%)
Respiratory system 19 (55.9%)
Joints 12 (35.3%)
Gastrointestinal system 7 (20.6%)
Skin 5 (14.7%)
Muscles 2 (5.9%)
Genitourinary system 1 (2.9%)
Liver 1 (2.9%)
Plasma creatinine (mg/dl) 6 ± 4.2 (range 0.8–19.4 mg/dl)
Proteinuria (g/24 h) 1.4 ± 0.96 (range 0.2–4.85 g/24 h)
CRP (mg/l) 72.8 ± 78 (range 3.4–272 mg/dl)
Oligoanuria 11 (32.3%)
Dialysis 14 (41.2%)
Plasma exchange 14 (41.2%)
Follow-up (months) 20 ± 22 (range 1–72 months)
Abbrev: MPO, myeloperoxidase; PR3, Proteinase 3; CRP, C-reactive proteinBMC Nephrology 2006, 7:16 http://www.biomedcentral.com/1471-2369/7/16
Page 5 of 13
(page number not for citation purposes)
Response to the treatment
A total of 24 patients (70.6%) overall responded to treat-
ment. 5/24 (20.8%) showed a complete response to the
treatment and 19/24 (79.2%) a partial one. Mean pCr
decreased from 2.1 ± 1.1 to 0.9 ± 0.1 mg/dl (p = 0.006) in
the patients who responded completely. In patients with
partial response to the treatment, pCr levels decreased
from 5.4 ± 2.4 to 3.1 ± 1.2 mg/dl (p = 0.004). In particu-
lar, renal function in partial responders improved in 5 of
19 and remained stable in 4 of 19. In the remaining 10
patients renal function gradually deteriorated and 4
patients finally reached ESRD at 23, 36, 51 and 61 months
after the diagnosis. The mean period of follow-up was 20
months (range 1–72 months, noting that the value of 1
month of follow up was attributed to those patients pre-
senting with dialysis dependent renal failure and not
responding to treatment at all).
Prognostic significance of presenting features
I. Clinical
Clinical characteristics at presentation of responders and
non- responders are comparatively listed in Table 4.
Responders were older and presented with significantly
lower levels of blood urea and creatinine at biopsy. CRP
levels were significantly lower in patients who responded
to the treatment. In particular, mean CRP levels at diagno-
sis were 14 ± 12 mg/l in completely responders, 52 ± 51
mg/l in those who responded partially (P = 0.009) and
143 ± 92 mg/l in non-responders (P < 0.0001). Other clin-
ical features did not differ significantly between respond-
ers and non-responders. On multivariate analysis, only
CRP levels at presentation were predictive of a response to
treatment (p = 0.024).
II. Histologic and immunohistologic
The mean percentage of glomeruli with crescents was
higher in responders (65 ± 32 vs. 47 ± 32), but the differ-
ence did not reach the level of statistical significance
(Table 4). Also, the distribution of cellular and fibrous
crescents was similar between the two groups. However,
the percentage of glomeruli with fibrocellular crescents
was significantly higher in non-responders (8 ± 20 vs. 38
± 52, p = 0.027). Normal glomeruli were recorded with-
out statistically significant difference between responders
and non-responders. The severity of cellular infiltration of
the TIN was similar in both groups. In contrast, non-
responders had significantly higher scores of TIN fibrosis,
tubular atrophy and arteriosclerosis compared with the
group of responders. The numbers of glomerular and
interstitial macrophages were similar in both groups
(Table 5). Also, the numbers of glomerular and interstitial
HLA-DR(+), PCNA(+), α-SMA(+) and LFA-1β(+) cells did
not differ significantly between responders and non-
responders (table 5). The glomerular expression of ICAM-
1 and C5b-9 was similar in both, responders and non-
responders, but the percentage of tubules expressing these
antigens was significantly higher in non-responders (fig-
ures 1, 2). In addition, the glomerular expression of TGF-
β1 was significantly higher in non-responders (figures 3,
4), but the intensity of TIN TGF-β1 expression was similar
to that of responders. On multivariate analysis, the per-
centage of tubules expressing C5b-9 (P  < 0.0001) was
shown to be the only independent factor predictive of the
response to treatment. The long term outcome of renal
function, as defined by the levels of pCr at the end of fol-
low up, correlated with the pCr and CRP levels at presen-
tation (p = 0.006 and p = 0.005, respectively), the severity
of TIN infiltration and fibrosis (p < 0.0001), the degree of
tubular atrophy and arterial sclerosis (p < 0.0001 and p =
0.049, respectively). The degree of TGF-β1 and C5b-9
expression in the TIN showed significant correlation with
the final pCr (p = 0.002 and p < 0.0001, respectively). On
multivariate analysis however, only the severity of TIN
infiltration and fibrosis and the expression of TGF-β1 in
the tubulointerstitium were independent predictors of the
long-term outcome.
III. The effect of ANCA
ANCA (+) patients tended to respond more successfully to
the treatment as compared with ANCA (-) patients (80%
vs. 57%, p = 0.008). In addition, there was a tendency
towards a better response to the treatment in PR3 (+)
patients than MPO (+) patients (89% vs. 75%) (Table 6),
although this difference did not reach the level of signifi-
cance. A comparison between the two groups of patients
showed that ANCA (+) patients were older (60 ± 13 vs. 42
± 20, p = 0.005), and had more severe proteinuria at
biopsy (2.21 ± 1.12 vs. 1.17 ± 0.77, p = 0.005) (Tables 7,
8). In addition, ANCA (+) patients had more frequently
focal glomerular necrosis in their glomeruli (65.4% vs.
Table 3: Phenotypical analysis of renal parenchymal cells
Glomeruli (/glom section) TIN (/mm2)
Monocyte/macrophages 15 ± 10 547 ± 198
HLA-DR (+) cells - 1129 ± 782
PCNA (+) cells 33 ± 16 748 ± 196
α-SMA(+)cells 34 ± 16 692 ± 273
LFA-1β (+) cells 15 ± 6 489 ± 142BMC Nephrology 2006, 7:16 http://www.biomedcentral.com/1471-2369/7/16
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37.5%). Also, ANCA (+) patients had more intense
glomerular TGF-β1 expression (1.14 ± 0.69 vs. 2.25 ±
0.96, p = 0.050) and higher numbers of PCNA (+) cells
and macrophages in the TIN (809 ± 170 vs. 581 ± 181, p
= 0.040 and 605 ± 194 vs. 581 ± 181, p = 0.041, respec-
tively). Interestingly, MPO (+) patients presented with less
Table 5: Immunohistological findings at presentation
Responders N = 24 Non responders N = 10 p
I. Glomeruli
PCNA(+) cells 38 ± 16 31 ± 16 NS
α-SMA(+)cells 30 ± 16 38 ± 17 NS
Monocytes/macrophages 16 ± 11 15 ± 8 NS
LFA-1β(+)cells 14 ± 5 22 ± 8 NS
TGF-β1 expression 1.0 ± 0.63 2.2 ± 0.84 0.046
ICAM-1 expression 1.67 ± 0.78 1.71 ± 0.75 NS
C5b-9 expression 2.14 ± 0.95 2.6 ± 0.54 NS
II. Tubulointerstitium
HLA-DR(+) cells 986 ± 702 1484 ± 1022 NS
PCNA(+)cells 845 ± 145 686 ± 160 NS
α-SMA(+)cells 732 ± 275 497 ± 224 NS
Monocytes/macrophages 580 ± 222 473 ± 144 NS
LFA-1β(+)cells 512 ± 151 460 ± 132 NS
ICAM-1 in tubules 29.3 ± 9.5 48.8 ± 4.9 <0.0001
C5b-9 in tubules 29.6 ± 8.5 38.9 ± 9.1 0.05
TGF-β1 in interstitium 1.57 ± 0.94 2.4 ± 0.55 NS
TGF-β1 in tubules 1.78 ± 0.80 2.4 ± 0.89 NS
ICAM-1in vessels 1.27 ± 0.46 1.10 ± 0.01 NS
C5b-9 in vessels 1.06 ± 0.26 1.01 ± 0.09 NS
Table 4: Clinical and histologic data at presentation
Responders N = 24 Non responders N = 10 p
I. Clinical
Age (years) 58 ± 16 44 ± 19 0.036
pCreatinine at biopsy (mg/dl) 4.8 ± 2.6 10.2 ± 5.8 0.001
pUrea at biopsy (mg/dl) 105.2 ± 29.8 184 ± 97.5 0.001
CRP (mg/l) 44 ± 49 143 ± 92 <0.0001
ESR (mm/1 h) 112 ± 28 118 ± 47 NS
24 h urinary albumin excretion (g) 1.26 ± 1.1 1.66 ± 0.64 NS
II. Histologic
Crescents (%) 65 ± 32 47 ± 32 NS
Cellular crescents 64 ± 43 49 ± 53 NS
Fibrocellular crescents 8 ± 20 38 ± 52 0.027
Fibrous crescents 12 ± 24 11 ± 2 NS
Obsolete glomeruli 27 ± 20 29 ± 27 NS
Focal necrosis 1.33 ± 0.48 1.60 ± 0.52 NS
TIN infiltration 1.19 ± 1.03 1.22 ± 0.97 NS
Tubular atrophy 0.95 ± 0.72 1.89 ± 1.16 0.011
TIN fibrosis 1.2 ± 0.99 2.22 ± 0.97 0.002
Arterial sclerosis 1.40 ± 1.07 1.67 ± 1.12 0.05
Abbrev: CRP, C-reactive protein, ESR, erythrocyte sedimentation rate, TIN, tubulointerstitialBMC Nephrology 2006, 7:16 http://www.biomedcentral.com/1471-2369/7/16
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TIN PCNA (+) cell infiltration (756 ± 166 vs. 947 ± 92, p
= 0.049) and TGF-β1 expression than PR3 (+) patients
(1.45 ± 0.7 vs. 2.67 ± 0.6, p = 0.017) (Tables 9, 10).
Conclusion
The results of the present study showed that 70 per cent of
our patients with IRPGN and moderate to severe disease
responded to the treatment. Combined treatment with
corticosteroids and cyclophosphamide induces remission
in 75–80% of patients with renal vasculitis according to
various reports [10-12]. The relatively lower rate of
response that was achieved in this study may be related to
late referral of most patients, since mean plasma creati-
nine at presentation was high enough (~6 mg/dl) and
41% of the patients were dialysis dependent. This study
corresponds with other reports according to which the
degree of renal function impairment at presentation
inversely correlates with the response to the treatment and
the subsequent renal outcome [3-12]. In order to deter-
mine the influence of other parameters on the response to
the treatment, we tested several clinical and pathological
factors independent of the level of initial renal function.
The percentage of crescents and particularly the percent-
age of cellular crescents did not differ between responders
and non-responders. Also the prevalence of fibrinoid
necrosis, which plays a role in the evolution of crescents,
was similar in both groups. These findings are in agree-
ment with previous studies reporting that both of these
histological lesions may be regarded as signs of active dis-
ease and hence are more likely to be reversed with the
treatment [5-10]. Contrary to other studies, normal
glomeruli were observed at even scores between the two
groups, denoting that the percentage of normal glomeruli
was insignificant as a determinant of renal function
impairment and prognosis of treatment response. In sup-
port of the histological findings, the numbers as well as
the type of cells (macrophages, myofibroblast-like cells,
proliferating cells, LFA-1β expressing cells) infiltrating the
glomeruli were remarkably similar in both groups.
Interestingly, fibrocellular crescents, in contrast to cellular
crescents, were more frequently found in non-responders,
while the proportion of fibrous crescents was identical in
the two groups. This means that these lesions are some-
Expression of C5b-9 in a non-responder and a responder Figure 1
Expression of C5b-9 in a non-responder and a responder.BMC Nephrology 2006, 7:16 http://www.biomedcentral.com/1471-2369/7/16
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how related to renal function recovery. Our findings indi-
cate that there may be a certain point of no return after
which a crescentic glomerulus loses its potential of recov-
ering to a histologically normal glomerulus. In untreated
patients the transformation of a cellular crescent to a
fibrocellular crescent seems to be a matter of time, since
they were found in patients with more advanced chronic
lesions in their biopsies indicating a more protracted
course of their disease[13,14]. The exact mechanisms
incriminated in the development and evolution of this
transformation in humans are not clear. However, it
seems that glomerular TGF-β1 may play a crucial role
since its expression was significantly more pronounced in
non-responders, despite the similar number of fibrous
crescents.
The severity of interstitial fibrosis and tubular atrophy as
well as the degree of arteriosclerosis were higher in non-
responders and this finding confirms previous observa-
tions [4-10]. Of interest is that the numbers of interstitial
macrophages, the numbers of activated or proliferating
interstitial cells as well as the numbers of interstitial
myofibroblasts (αSMA (+) cells) did not differ between
responders and non-responders. In addition, TGF-β1
expression in the tubulointerstitium was found to be sim-
ilar in both groups. Our results suggest that other factors,
such as the activation of tubular cells indicated by the de
novo expression of ICAM-1 and C5b-9, may be of impor-
tance, as is the case with other forms of glomerular dis-
eases [15-17]. Activated tubular cells are capable of
synthesizing numerous cytokines, adhesion molecules,
complement components and extracellular
matrix[18,19]. The degree of expression of C5b-9 by the
tubules also seems to be highly predictive of subsequent
renal outcome in different glomerulopathies [20-23].
Interestingly, in our study the degree of this expression
was the only independent factor that predicted the
response to the treatment.
ANCA (+) patients were older, had significantly greater
proteinuria compared to ANCA (-) patients and they
showed more prominent glomerular expression of TGF-
β1 as well as more numerous proliferating interstitial
cells. Also, fibrinoid necrosis was more commonly found
in ANCA (+) than in ANCA (-) patients. An increased like-
lihood between ANCA positivity and glomerular necrosis
Expression of C5b-9 in a responder Figure 2
Expression of C5b-9 in a responder.BMC Nephrology 2006, 7:16 http://www.biomedcentral.com/1471-2369/7/16
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has never been reported. Whether ANCA and particularly
PR3-ANCA, as our findings could suggest, bind to the
endothelium and increase the possibility of glomerular
necrosis should be further investigated. Irrespective of the
exact mechanisms, our findings indicate that increased
proteinuria in ANCA (+) patients may be associated with
early deposition of TGF-β1 in the glomeruli and, hence,
predispose to an increased likelihood of sclerosis.
Whether proteinuria is the cause of the increased intersti-
tial cell proliferation in the ANCA (+) group of patients is
not known. If this is the case, however, it does not seem to
involve tubular cell activation, as the expression of ICAM-
1 and C5b-9 by the tubules was similar between ANCA
(+) and ANCA (-) patients. Certainly, the number of
patients included in this study is small and our results
need to be confirmed by larger trials, where the two
groups will be evenly represented. However, these find-
ings may help in the establishment of new treatment strat-
egies for this disease.
Eighty percent of ANCA (+) patients showed a complete
(62%) or partial response (15%) to the treatment, while
only 50% of the ANCA (-) group showed a similar
response (38% complete and 12% partial response). The
reason for this difference is not clear and relevant data are
scarce in the literature. For example, Adu et al reported
patients with microscopic polyangiitis with no clinical or
laboratory differences between ANCA (+) and ANCA (-)
patients[24]. Others, however, found fewer relapses and a
more favorable outcome in ANCA (-) patients[25,26].
Certainly different diagnostic criteria and treatment poli-
cies may affect the interpretation of various reports. How-
ever, the increased proliferation of interstitial cells found
in ANCA (+) patients in our study may reflect an increased
susceptibility of these patients to treatment and this could
explain in part the favorable response of these patients. In
support of this view, PR3-ANCA (+) patients who had
more numerous interstitial proliferating cells compared to
MPO-ANCA (+) patients showed also a tendency towards
a better response to the treatment (89% vs. 75%). Several
in vitro studies have shown that peripheral blood mono-
nuclear cells proliferate more actively with PR3 than with
MPO [27-29]. In addition IgG fractions from anti-PR3 (+)
patients were more potent activators of the respiratory
burst and degranulation than IgG fractions from anti-
MPO (+) patients[5,27,28]. These observations suggest
Expression of TGF-β1 in a responder Figure 3
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that cell activation markers may contribute to the differ-
ences in the response to the treatment between anti-PR3
and anti-MPO associated renal vasculitis. This may alter
the perspective regarding the intensity and the duration of
the immunosuppressive therapy in these patients. How-
ever, our results need to be confirmed by larger studies
before they establish a new parameter to tailor treatment.
In conclusion, baseline renal function is the best clinical
predictor of a response to therapy in patients with IRPGN.
Fibrocellular, but not cellular, fibrous crescents or fibri-
noid necrosis seem to be associated with a poorer
response to therapy. Chronic interstitial lesions as well as
the extent of tubular cell activation may also carry an
increased risk for no response. ANCA (+) patients and par-
ticularly PR3-ANCA (+) seem to respond better to the
treatment. This may be related to the increased rate of
interstitial cell proliferation, but this contention should
be further investigated.
Expression of TGF-β1 in a non-responder Figure 4
Expression of TGF-β1 in a non-responder.
Table 6: Response to treatment according to ANCA status
ANCA(+) n = 26 ANCA(-) n = 8 MPO(+)-ANCA n = 17 PR3(+)-ANCA n = 9
Response 20/26 (77%) 4/8 (50%) 12/17 (71%) 8/9 (89%)
complete 16/26 (62%) 3/8 (38%) 9/17 (53%) 1/9 (11%)
partial 4/26 (15%) 1/8 (12%) 3/17 (17%) 7/9 (78%)
No response 6/26 (23%) 4/8 (50%) 5/17 (29%) 1/9 (11%)
See text for detailsBMC Nephrology 2006, 7:16 http://www.biomedcentral.com/1471-2369/7/16
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Table 8: Differences in immunohistochemical findings between ANCA (+) and ANCA (+) patients
ANCA (+) N = 26 ANCA (-) N = 8 p
I. Glomeruli
PCNA(+) cells 36 ± 16 26 ± 16 NS
α-SMA(+)cells 34 ± 15 32 ± 19 NS
Monocytes/macrophages 15 ± 10 14 ± 10 NS
LFA-1β(+)cells 15 ± 6 10 ± 4 NS
TGF-β1 expression 1.14 ± 0.69 2.25 ± 0.96 0.05
ICAM-1 expression 1.53 ± 0.64 2.25 ± 0.96 NS(0.06)
C5b-9 expression 2.27 ± 0.96 2.25 ± 0.5 NS
II. Tubulointerstitium
HLA-DR(+) cells 1207 ± 831 736 ± 300 NS
PCNA(+)cells 809 ± 170 581 ± 181 0.041
α-SMA(+)cells 728 ± 260 556 ± 318 NS
Monocytes/macrophages 570 ± 204 452 ± 156 NS
LFA-1β(+)cells 485 ± 149 517 ± 86 NS
ICAM-1 in tubules 34.2 ± 11.4 45.5 ± 12.5 NS
C5b-9 in tubules 32,3 ± 9,7 32,7 ± 8.16 NS
TGF-β1 in interstitium 1.73 ± 0.8 2 ± 1.41 NS
TGF-β1 in tubules 1.87 ± 0.83 2.25 ± 0.96 NS
ICAM-1in vessels 1,21 ± 0,42 1.0 ± 0.01 NS
C5b-9 in vessels 1.06 ± 0.25 1.01 ± 0.09 NS
Table 7: Clinical and histologic differences between ANCA (+) and ANCA (-) patients
ANCA (+) N = 26 ANCA (-) N = 8 p
I. Clinical
Age (years) 60 ± 13 42 ± 20 0,005
pCreatinine at biopsy (mg/dl) 6.11 ± 4.7 5.7 ± 1.8 NS
pUrea at biopsy (mg/dl) 128.3 ± 69.3 109.4 ± 25.5 NS
CRP (mg/l) 64.7 ± 75 99 ± 86 NS
ESR (mm/1 h) 116 ± 28 108 ± 44 NS
24 h urinary albumin excretion (g) 2.21 ± 1.12 1.17 ± 0.77 0,005
II. Histologic
Crescents (%) 63 ± 33 52 ± 32 NS
Cellular crescents 59 ± 44 51 ± 47 NS
Fibrocellular crescents 11 ± 26 51 ± 47 NS(0.06)
Fibrous crescents 12 ± 24 11 ± 21 NS
Obsolete glomeruli 25 ± 23 35 ± 19 NS
Focal necrosis 1.34 ± 0.48 1.62 ± 0.52 NS
TIN infiltration 1.36 ± 1.13 1.87 ± 0.99 NS
Tubular atrophy 1.13 ± 0.97 1.5 ± 0.93 NS
TIN fibrosis 1.4 ± 1.1 1.59 ± 0.5 NS
Arterial sclerosis 1.79 ± 1.06 2.25 ± 0.96 0.05
Abbrev: CRP, C-reactive protein, ESR, erythrocyte sedimentation rate, TIN, tubulointerstitialBMC Nephrology 2006, 7:16 http://www.biomedcentral.com/1471-2369/7/16
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Table 10: Differences in immunohistochemical findings between MPO-ANCA (+) and PR3-ANCA (+) patients
MPO-ANCA (+) N = 17 PR3-ANCA (+) N = 9 p
I. Glomeruli
PCNA(+) cells 28 ± 14 47 ± 12 NS
α-SMA(+)cells 36 ± 12 32 ± 23 NS
Monocytes/macrophages 17 ± 12 12 ± 3 NS
LFA-1β(+)cells 14 ± 5 21 ± 8 NS
TGF-β1 expression 1.0 ± 0.7 1.5 ± 0.7 NS
ICAM-1 expression 1.5 ± 0.67 1.66 ± 0.58 NS
C5b-9 expression 2.2 ± 1.08 2.5 ± 0.58 NS
II. Tubulointerstitium
HLA-DR(+) cells 1293 ± 894 866 ± 467 NS
PCNA(+)cells 757 ± 166 947 ± 92 0.041
α-SMA(+)cells 702 ± 222 779 ± 348 NS
Monocytes/macrophages 550 ± 181 614 ± 264 NS
LFA-1β(+)cells 469 ± 157 552 ± 106 NS
ICAM-1 in tubules 35.4 ± 10.8 29.4 ± 15 NS
C5b-9 in tubules 30.6 ± 9,4 37.3 ± 10.2 NS
TGF-β1 in interstitium 1.45 ± 0.7 2.67 ± 0.6 0.017
TGF-β1 in tubules 1.67 ± 0.78 2.25 ± 0.96 NS
ICAM-1in vessels 1,18 ± 0,4 1.3 ± 0.57 NS
C5b-9 in vessels 1.08 ± 0.29 1.0 ± 0.07 NS
Table 9: Clinical and histologic differences between MPO-ANCA (+) and PR3-ANCA (+) patients
MPO-ANCA (+) N = 17 PR3-ANCA (+) N = 9 p
I. Clinical
Age (years) 63 ± 10 55 ± 17 NS
pCreatinine at biopsy (mg/dl) 5.9 ± 4.5 6.5 ± 5.3 NS
pUrea at biopsy (mg/dl) 123 ± 56 138 ± 92 NS
CRP (mg/l) 54 ± 63 84 ± 95 NS
ESR (mm/1 h) 116 ± 34 116 ± 16 NS
24 h urinary albumin excretion (g) 1.24 ± 0.81 1.04 ± 0.73 NS
II. Histologic
Crescents (%) 61 ± 35 67 ± 28 NS
Cellular crescents 56 ± 44 66 ± 46 NS
Fibrocellular crescents 13 ± 30 8 ± 17 NS
Fibrous crescents 10 ± 21 15 ± 31 NS
Obsolete glomeruli 28 ± 22 20 ± 24 NS
Focal necrosis 1.41 ± 0.5 1.22 ± 0.44 NS
TIN infiltration 1.53 ± 1.12 1.0 ± 1.15 NS
Tubular atrophy 1.4 ± 0.98 0.62 ± 0.74 NS
TIN fibrosis 1.5 ± 1.09 1.07 ± 1.09 NS
Arterial sclerosis 1.94 ± 1.0 1.5 ± 1.19 NS
Abbrev: CRP, C-reactive protein, ESR, erythrocyte sedimentation rate, TIN, tubulointerstitialPublish with BioMed Central    and   every 
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